Association between systemic inflammation response index and risk of major adverse cardiovascular events in adults with and without metabolic syndrome: a prospective cohort study in Shanghai, Pudong - Report - MDSpire
Advertisement
Association between systemic inflammation response index and risk of major adverse cardiovascular events in adults with and without metabolic syndrome: a prospective cohort study in Shanghai, Pudong
Clinical Report: Link Between Systemic Inflammation Response Index and MACE Risk
Overview
This study investigates the prognostic value of the systemic inflammation response index (SIRI) for major adverse cardiovascular events (MACE) among adults with and without metabolic syndrome (MS). Findings indicate that elevated SIRI is independently associated with increased MACE risk, particularly in individuals with MS.
Background
Cardiovascular disease (CVD) is a leading cause of mortality globally, with metabolic syndrome (MS) recognized as a significant modifiable risk factor. Chronic low-grade inflammation is a key mechanism linking MS to adverse cardiovascular outcomes. Identifying reliable inflammatory biomarkers like SIRI could enhance cardiovascular risk prediction and management.
Data Highlights
Group
SIRI Quartile
Hazard Ratio (HR)
95% Confidence Interval (CI)
P-value
Non-MS
Lowest
1.00
-
-
MS
Highest
2.33
1.64–3.30
< 0.001
MS
Highest vs Lowest
1.38
1.08-1.77
0.01
Key Findings
Higher SIRI quartiles correlate with unfavorable metabolic profiles in both MS and non-MS groups.
Participants with MS in the highest SIRI quartile have a 2.33 times greater risk of MACE compared to non-MS participants in the lowest quartile.
Among participants with MS, the highest SIRI quartile shows a 38% increased risk of MACE compared to the lowest quartile.
RCS analysis reveals a linear positive association between SIRI and MACE risk in participants with MS.
A significant non-linear interaction exists between SIRI and fasting plasma glucose.
Clinical Implications
SIRI may serve as a useful biomarker for cardiovascular risk stratification, particularly in patients with metabolic syndrome. Clinicians should consider integrating SIRI assessments into routine evaluations for individuals at high risk of major adverse cardiovascular events.
Conclusion
Elevated SIRI is linked to a higher risk of incident MACE, with metabolic syndrome status significantly influencing this association. Further research may clarify the role of SIRI in cardiovascular risk management.
